Microsoft vs Novo Nordisk A/S — how do they compare? Microsoft trades at $499.61 (market cap $3.74T), while Novo Nordisk A/S trades at $45.88 (market cap $207.85B). The key difference: Microsoft is far larger — about 18× Novo Nordisk A/S's market cap, and Novo Nordisk A/S pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| MSFT | NVO | |
|---|---|---|
Market Cap | $3.74T | $207.85B |
Volume | 36,654,621 | — |
Sector | Technology | Health |
52-Week High | $542.07 | $63.98 |
52-Week Low | $352.83 | $35.29 |
Enterprise Value | $3.72T | $222.55B |
Dividend Yield | 0.72% | 3.81% |
Signals from Pluang's Aura AI — not financial advice
Microsoft (MSFT) trades at $506.06, up 1.21% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with $281.72B revenue, 40.31% net margin, and consistent earnings beats. Analyst consensus remains overwhelmingly positive with 80.49% buy ratings and $552.73 price target, representing 9.2% upside potential. Recent news highlights Microsoft's AI leadership and cloud computing strength.
Microsoft presents a compelling investment case with strong financial performance and AI-driven growth prospects. Key opportunities include Azure cloud expansion and Copilot adoption, while risks involve increased capital expenditures and competitive pressures. The stock's current valuation at 28.19 P/E appears reasonable given growth trajectory, though investors should monitor execution on AI investments and macroeconomic conditions affecting tech spending.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →